CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
The findings, presented today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight advances researchers are making to develop more effective therapies for patients...